Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
An update on respiratory syncytial virus antiviral agents
Autore:
Prince, GA;
Indirizzi:
Virion Syst Inc, Rockville, MD 20850 USA Virion Syst Inc Rockville MD USA20850 Syst Inc, Rockville, MD 20850 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 2, volume: 10, anno: 2001,
pagine: 297 - 308
SICI:
1354-3784(200102)10:2<297:AUORSV>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
MONOCLONAL-ANTIBODY; TRACT INFECTION; RSV INFECTIONS; YOUNG-CHILDREN; HIGH-RISK; IN-VITRO; KAPPA-B; RIBAVIRIN; INFANTS; DISEASE;
Keywords:
anti-inflammatory; antiviral; respiratory syncytial virus; RSV; therapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
90
Recensione:
Indirizzi per estratti:
Indirizzo: Prince, GA Virion Syst Inc, 9610 Med Ctr Dr,Suite 100, Rockville, MD 20850USA Virion Syst Inc 9610 Med Ctr Dr,Suite 100 Rockville MD USA 20850
Citazione:
G.A. Prince, "An update on respiratory syncytial virus antiviral agents", EXPERT OP I, 10(2), 2001, pp. 297-308

Abstract

Respiratory syncytial virus (RSV), the most common cause of lower respiratory tract disease in infants and young children, is a ubiquitous respiratory pathogen, infecting or reinfecting much of the population every year and causing severe, sometimes fatal disease in high-risk populations of infantsand adults, particularly in developing countries. Spurred by the medical and economic burdens of RSV disease and enticed by the economic potential oftherapeutic drugs, particularly in the absence to date of a safe and effective RSV vaccine, scientists in many industrial, academic and government laboratories have developed a wide variety of candidate RSV antiviral agents. Most of these have been screened thus far only in cell culture, a few in animal models. Aside from ribavirin, however, none has proven effective in therapeutic clinical trials and even ribavirin usage has declined precipitously in recent years due to concerns over efficacy, safety, ease of use and cost. All of the antiviral compounds discussed in this review were evaluated primarily for their ability to reduce viral load, with little or no attention paid to the role of host inflammation in the pathogenesis of RSV disease. Recent research has highlighted the prominent role of inflammatory mediators and an increasing number of reports suggest that a therapeutic strategy that combines antiviral and anti-inflammatory components will be the most effective way of treating RSV disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 07:16:39